{"address1": "150 West 4th Ave", "city": "Vancouver", "state": "BC", "zip": "V5Y 1G6", "country": "Canada", "phone": "604 559 9005", "website": "https://www.abcellera.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.", "fullTimeEmployees": 596, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl L.G. Hansen Ph.D.", "age": 49, "title": "CEO, President & Chairperson", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 714939, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Booth M.B.A.", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 674555, "exercisedValue": 0, "unexercisedValue": 25365500}, {"maxAge": 1, "name": "Dr. Veronique  Lecault Ph.D.", "age": 39, "title": "CTO & Director", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 650587, "exercisedValue": 1409524, "unexercisedValue": 5575004}, {"maxAge": 1, "name": "Mr. Tryn T. Stimart Esq., J.D., M.Sc.", "age": 54, "title": "Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 667690, "exercisedValue": 0, "unexercisedValue": 7349760}, {"maxAge": 1, "name": "Ms. Tiffany  Chiu B.Sc., Ph.D.", "title": "Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Graham  Craig M.Sc.", "title": "Director of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Murray  McCutcheon Ph.D.", "title": "Senior Vice President of Partnering", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Neil  Aubuchon B.A., M.B.A.", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 684813, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Clarke M.A.I.C.D., Ph.D.", "title": "Senior Vice President of Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul  Colussi Ph.D.", "title": "Site Head & VP of Complex Membrane Protein Technologies", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 5, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.23, "open": 2.23, "dayLow": 2.06, "dayHigh": 2.23, "regularMarketPreviousClose": 2.23, "regularMarketOpen": 2.23, "regularMarketDayLow": 2.06, "regularMarketDayHigh": 2.23, "payoutRatio": 0.0, "beta": 0.452, "forwardPE": -3.1666665, "volume": 4283145, "regularMarketVolume": 4283145, "averageVolume": 4128228, "averageVolume10days": 3351370, "averageDailyVolume10Day": 3351370, "bid": 2.06, "ask": 2.11, "bidSize": 16, "askSize": 16, "marketCap": 622794880, "fiftyTwoWeekLow": 2.06, "fiftyTwoWeekHigh": 4.75, "priceToSalesTrailing12Months": 21.600073, "fiftyDayAverage": 2.8165, "twoHundredDayAverage": 2.8118, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 62544228, "profitMargins": 0.0, "floatShares": 202801468, "sharesOutstanding": 297988000, "sharesShort": 22787356, "sharesShortPriorMonth": 20096109, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0765, "heldPercentInsiders": 0.22883, "heldPercentInstitutions": 0.42270002, "shortRatio": 4.6, "shortPercentOfFloat": 0.099, "impliedSharesOutstanding": 297988000, "bookValue": 3.571, "priceToBook": 0.58527017, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -162856992, "trailingEps": -0.55, "forwardEps": -0.66, "enterpriseToRevenue": 2.169, "enterpriseToEbitda": -0.279, "52WeekChange": -0.5228311, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 2.09, "targetHighPrice": 28.0, "targetLowPrice": 4.0, "targetMeanPrice": 11.85714, "targetMedianPrice": 9.0, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 625614016, "totalCashPerShare": 2.099, "ebitda": -223916992, "totalDebt": 65364000, "quickRatio": 8.951, "currentRatio": 9.807, "totalRevenue": 28833000, "debtToEquity": 6.189, "revenuePerShare": 0.098, "returnOnAssets": -0.12408, "returnOnEquity": -0.14749, "grossProfits": -138426000, "freeCashflow": -177765744, "operatingCashflow": -108556000, "revenueGrowth": -0.45, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -8.0703, "financialCurrency": "USD", "symbol": "ABCL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NMS", "messageBoardId": "finmb_280568380", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "preMarketTime": 1743589983, "regularMarketTime": 1743537602, "regularMarketChangePercent": -6.2780313, "regularMarketPrice": 2.09, "shortName": "AbCellera Biologics Inc.", "longName": "AbCellera Biologics Inc.", "marketState": "PRE", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "preMarketChange": 0.05000019, "preMarketChangePercent": 2.3923538, "preMarketPrice": 2.14, "regularMarketChange": -0.1400001, "regularMarketDayRange": "2.06 - 2.23", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 4128228, "fiftyTwoWeekLowChange": 0.029999971, "fiftyTwoWeekLowChangePercent": 0.014563093, "fiftyTwoWeekRange": "2.06 - 4.75", "fiftyTwoWeekHighChange": -2.66, "fiftyTwoWeekHighChangePercent": -0.56, "fiftyTwoWeekChangePercent": -52.283108, "earningsTimestamp": 1740690300, "earningsTimestampStart": 1746442740, "earningsTimestampEnd": 1746792000, "earningsCallTimestampStart": 1740693600, "earningsCallTimestampEnd": 1740693600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.55, "epsForward": -0.66, "epsCurrentYear": -0.66333, "priceEpsCurrentYear": -3.1507695, "fiftyDayAverageChange": -0.72650003, "fiftyDayAverageChangePercent": -0.2579443, "twoHundredDayAverageChange": -0.7218001, "twoHundredDayAverageChangePercent": -0.2567039, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "displayName": "AbCellera Biologics", "trailingPegRatio": null}